The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system

D. Del Castillo, Leopoldo Raij, P. J. Shultz, J. P. Tolins

Research output: Contribution to journalArticle

Abstract

In a subset of dialysis patients, erythropoietin (rHuEpo) treatment exacerbates hypertension. The mechanism of this pressor effect is unknown; however, it has been suggested that decreased endogenous nitric oxide (NO) activity may play a role. To explore this hypothesis, SpragueDawley rats were given rHuEpo (150 U/kg s.c. three times per week) or corresponding vehicle. Blood pressure, haematocrit, and urinary excretion of the stable NO metabolites, nitrite (NO2) and nitrate (NO3), were determined at baseline and 3 weeks. After 3 weeks of rHuEpo treatment there was a significant increase in blood pressure and haematocrit, while in vehicle-treated rats blood pressure and haematocrit remained at basal levels. Urinary excretion of NO2+NO3increased compared to basal in rHuEpo, but not vehicle rats. Thus in normal rats rHuEpo does have a significant pressor effect, but this is not associatedwith decreased activity of the endogenous NO system. Thus decreased endogenous NO activity is not responsible for rHuEpo-associated hypertension. These data further suggest that endogenous NO activity is increased in rHuEpo-treated rats, perhaps as a counter-regulatory mechanism that limits the pressor effect. Whether this mechanism is active in the setting of rHuEpo-treated chronic renal failure in humans is unknown.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalNephrology Dialysis Transplantation
Volume10
Issue number4
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Erythropoietin
Nitric Oxide
Hematocrit
Blood Pressure
Hypertension
Nitrites
Nitrates
Chronic Kidney Failure
Dialysis
Therapeutics

Keywords

  • Erythropoietin
  • Hypertension
  • Nitric oxide
  • No

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. / Del Castillo, D.; Raij, Leopoldo; Shultz, P. J.; Tolins, J. P.

In: Nephrology Dialysis Transplantation, Vol. 10, No. 4, 01.01.1995, p. 505-508.

Research output: Contribution to journalArticle

Del Castillo, D. ; Raij, Leopoldo ; Shultz, P. J. ; Tolins, J. P. / The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. In: Nephrology Dialysis Transplantation. 1995 ; Vol. 10, No. 4. pp. 505-508.
@article{6a6920dc1cf5498b954c6237316eae4b,
title = "The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system",
abstract = "In a subset of dialysis patients, erythropoietin (rHuEpo) treatment exacerbates hypertension. The mechanism of this pressor effect is unknown; however, it has been suggested that decreased endogenous nitric oxide (NO) activity may play a role. To explore this hypothesis, SpragueDawley rats were given rHuEpo (150 U/kg s.c. three times per week) or corresponding vehicle. Blood pressure, haematocrit, and urinary excretion of the stable NO metabolites, nitrite (NO2) and nitrate (NO3), were determined at baseline and 3 weeks. After 3 weeks of rHuEpo treatment there was a significant increase in blood pressure and haematocrit, while in vehicle-treated rats blood pressure and haematocrit remained at basal levels. Urinary excretion of NO2+NO3increased compared to basal in rHuEpo, but not vehicle rats. Thus in normal rats rHuEpo does have a significant pressor effect, but this is not associatedwith decreased activity of the endogenous NO system. Thus decreased endogenous NO activity is not responsible for rHuEpo-associated hypertension. These data further suggest that endogenous NO activity is increased in rHuEpo-treated rats, perhaps as a counter-regulatory mechanism that limits the pressor effect. Whether this mechanism is active in the setting of rHuEpo-treated chronic renal failure in humans is unknown.",
keywords = "Erythropoietin, Hypertension, Nitric oxide, No",
author = "{Del Castillo}, D. and Leopoldo Raij and Shultz, {P. J.} and Tolins, {J. P.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1093/ndt/10.4.505",
language = "English (US)",
volume = "10",
pages = "505--508",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system

AU - Del Castillo, D.

AU - Raij, Leopoldo

AU - Shultz, P. J.

AU - Tolins, J. P.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - In a subset of dialysis patients, erythropoietin (rHuEpo) treatment exacerbates hypertension. The mechanism of this pressor effect is unknown; however, it has been suggested that decreased endogenous nitric oxide (NO) activity may play a role. To explore this hypothesis, SpragueDawley rats were given rHuEpo (150 U/kg s.c. three times per week) or corresponding vehicle. Blood pressure, haematocrit, and urinary excretion of the stable NO metabolites, nitrite (NO2) and nitrate (NO3), were determined at baseline and 3 weeks. After 3 weeks of rHuEpo treatment there was a significant increase in blood pressure and haematocrit, while in vehicle-treated rats blood pressure and haematocrit remained at basal levels. Urinary excretion of NO2+NO3increased compared to basal in rHuEpo, but not vehicle rats. Thus in normal rats rHuEpo does have a significant pressor effect, but this is not associatedwith decreased activity of the endogenous NO system. Thus decreased endogenous NO activity is not responsible for rHuEpo-associated hypertension. These data further suggest that endogenous NO activity is increased in rHuEpo-treated rats, perhaps as a counter-regulatory mechanism that limits the pressor effect. Whether this mechanism is active in the setting of rHuEpo-treated chronic renal failure in humans is unknown.

AB - In a subset of dialysis patients, erythropoietin (rHuEpo) treatment exacerbates hypertension. The mechanism of this pressor effect is unknown; however, it has been suggested that decreased endogenous nitric oxide (NO) activity may play a role. To explore this hypothesis, SpragueDawley rats were given rHuEpo (150 U/kg s.c. three times per week) or corresponding vehicle. Blood pressure, haematocrit, and urinary excretion of the stable NO metabolites, nitrite (NO2) and nitrate (NO3), were determined at baseline and 3 weeks. After 3 weeks of rHuEpo treatment there was a significant increase in blood pressure and haematocrit, while in vehicle-treated rats blood pressure and haematocrit remained at basal levels. Urinary excretion of NO2+NO3increased compared to basal in rHuEpo, but not vehicle rats. Thus in normal rats rHuEpo does have a significant pressor effect, but this is not associatedwith decreased activity of the endogenous NO system. Thus decreased endogenous NO activity is not responsible for rHuEpo-associated hypertension. These data further suggest that endogenous NO activity is increased in rHuEpo-treated rats, perhaps as a counter-regulatory mechanism that limits the pressor effect. Whether this mechanism is active in the setting of rHuEpo-treated chronic renal failure in humans is unknown.

KW - Erythropoietin

KW - Hypertension

KW - Nitric oxide

KW - No

UR - http://www.scopus.com/inward/record.url?scp=85047696318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047696318&partnerID=8YFLogxK

U2 - 10.1093/ndt/10.4.505

DO - 10.1093/ndt/10.4.505

M3 - Article

AN - SCOPUS:85047696318

VL - 10

SP - 505

EP - 508

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 4

ER -